APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer
Dr. Shearman, a pharma and biotech industry executive with an extensive track record of achievements in drug discovery and development, will lead the strategy and execution of the company’s clinical therapeutic and diagnostic programs CAMBRIDGE, Mass., Aug. 28, 2023 (GLOBE